Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$12.51 - $22.75 $875,700 - $1.59 Million
-70,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$17.43 - $24.34 $1.22 Million - $1.7 Million
70,000 New
70,000 $1.49 Million

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $289M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Sphera Funds Management Ltd. Portfolio

Follow Sphera Funds Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sphera Funds Management Ltd. with notifications on news.